US Pharma's Financialized Business Model
| Year of publication: |
2017
|
|---|---|
| Authors: | Lazonick, William |
| Other Persons: | Hopkins, Matt (contributor) ; Jacobson, Ken (contributor) ; Sakinç, Mustafa Erdem (contributor) ; Tulum, Öner (contributor) |
| Publisher: |
[2017]: [S.l.] : SSRN |
| Subject: | Pharmaindustrie | Pharmaceutical industry | Geschäftsmodell | Business model | Finanzmarkt | Financial market |
| Description of contents: |
Price gouging in the US p ...
|
freely available
| Extent: | 1 Online-Ressource (27 p) |
|---|---|
| Series: | |
| Type of publication: | Book / Working Paper |
| Language: | English |
| Notes: | Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments July 13, 2017 erstellt |
| Other identifiers: | 10.2139/ssrn.3035529 [DOI] |
| Classification: | d22 ; D24 - Production; Capital and Total Factor Productivity; Capacity ; D40 - Market Structure and Pricing. General ; G35 - Payout Policy ; H51 - Government Expenditures and Health ; L10 - Market Structure, Firm Strategy, and Market Performance. General ; L21 - Business Objectives of the Firm ; L51 - Economics of Regulation ; L65 - Chemicals; Rubber; Drugs; Biotechnology ; M52 - Compensation and Compensation Methods and Their Effects (stock options, fringe benefits, incentives, family support programs) |
| Source: | ECONIS - Online Catalogue of the ZBW |
Persistent link: https://www.econbiz.de/10012948021